title: Letter to the Editor; P. Van Damme et al. Vaccine 34 (2016) 757-761.
authors.affiliation: GSK Vaccines, Wavre, Belgium. Electronic address: martin.f.ryser@gsk.com.
authors.forename: Martin
authors.initials: M
authors.lastname: Ryser
authors.affiliation: GSK Vaccines, Wavre, Belgium.
authors.forename: Valérie
authors.initials: V
authors.lastname: Berlaimont
authors.affiliation: GSK Vaccines, Wavre, Belgium.
authors.forename: Attila
authors.initials: A
authors.lastname: Mihalyi
mesh_terms: D006801:Humans; D008297:Male; D017063:Outcome Assessment, Health Care; D011471:Prostatic Neoplasms; D014612:Vaccines; D015164:Vaccines, Inactivated
chemical_list: D014612:Vaccines; D015164:Vaccines, Inactivated